Cancer Research Institute (CRI) shared a post on LinkedIn:
“In a new study, researchers, including CRI Scientific Advisory Council member Dr. Thomas Gajewski of the University of Chicago, observed that patients with metastatic melanoma who did not respond to immune checkpoint inhibitors had DNA with differences not found in the DNA of those who did respond. NYU Langone Health describes how these findings ‘help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do not respond to the latest cancer treatments.’ Discover.”
More posts featuring CRI.